Centogene NV - notizie pubblicate 131 - letture 2.818


Centogene NV

CENTOGENE NV

C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development

Pdf version tucson, ariz. and cambridge, mass. and rostock, germany and berlin, june 20, 2024 (globe newswire) -- critical path institute (c-path), a leader in forming collaboratio ...

20.06.2024
Centogene NV

CENTOGENE NV

C Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development Form 6 K

C-path and centogene mou to enhance collaboration in lysosomal disease research and drug development tucson, ariz., cambridge, mass., and rostock, germany and berlin, june 20, 2024 ...

20.06.2024
Centogene NV

CENTOGENE NV

Minutes of the 2024 Annual General Meeting of Shareholders - Centogene N.V.

Docusign envelope id: a03a1d50-20f1-415d-af16-6ad3ec752a21 minutes of the annual general meeting of shareholders centogene n.v. may 31, 2024 minutes of the annual general meeting o ...

31.05.2024
Centogene NV

CENTOGENE NV

CENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General Meeting

Pdf version cambridge, mass. and rostock, germany and berlin, may 31, 2024 (globe newswire) -- centogene n.v. (nasdaq: cntg) (the "company"), the essential life science p ...

31.05.2024
Centogene NV

CENTOGENE NV

Iran Notice - Form IRANNOTICE

Centogene n.v. | am strande 7 | 18055 rostock, germany u.s. securities and exchange commission 100 f street, n.e. washington, d.c. 20549 united states may 17, 2024 re: notice of di ...

17.05.2024
Centogene NV

CENTOGENE NV

CENTOGENE Secures Approx. $20 Million to Strengthen Cash Position

Pdf version expanding relationship with lifera, a biopharma company owned by the pif cambridge, mass. and rostock, germany, and berlin, may 15, 2024 (globe newswire) -- centogene n ...

15.05.2024
Centogene NV

CENTOGENE NV

CENTOGENE Reports Full Year 2023 Financial Results and Recent Business Highlights

Pdf version reported full year 2023 total revenues of 2% growth at €48.5 million secured approximately usd 20 million - strengthening cash position and expanding relationship wit ...

15.05.2024
Centogene NV

CENTOGENE NV

KSA RECEIVABLES TRANSFER AGREEMENT - Form 6-K

Ksa receivables transfer agreement __________________________________________________________ al-tatweer towers, 7th floor, tower 1 king fahad highway p.o. box 17411 riyadh 11484, ...

15.05.2024
Centogene NV

CENTOGENE NV

CENTOGENE Reports Full Year 2023 Financial Results and Recent Business Highlights - Form 6-K

Centogene reports full year 2023 financial results and recent business highlights • reported full year 2023 total revenues of 2% growth at €48.5 million • secured approximate ...

15.05.2024
Centogene NV

CENTOGENE NV

Annual Report for Fiscal Year Ending December 31, 2023 (Form 20-F)

Table of contents united states securities and exchange commission washington, d.c. 20549 form 20-f (mark one) ☐ registration statement pursuant to section 12(b) or (g) of the se ...

15.05.2024
Centogene NV

CENTOGENE NV

Voting Proxy AGM 2024

Voting proxy the undersigned name : address : acting on behalf of (only to be completed if relevant) name : address : (the "principal"). declares as follows the principal ...

15.05.2024
Centogene NV

CENTOGENE NV

Convening Notice and Agenda (incl. explanatory notes) (AGM 2024)

Convening notice this is the convening notice for the annual general meeting of shareholders of centogene n.v. (the "company") to be held on may 31, 2024 at 11.00 a.m. ce ...

15.05.2024
Centogene NV

CENTOGENE NV

CENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher Disease - Form 6-K

Centogene and evotec discover promising new molecule to treat gaucher disease · centogene to receive license fee providing evotec with r&d license to complete next phase of pr ...

14.05.2024
Centogene NV

CENTOGENE NV

CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse Patients - Form 6-K

Centogene biodatabank grows to incorporate disease insights from over 850,000 diverse patients fueling the diagnosis of over 2,500 rare and neurodegenerative diseases, more than 30 ...

10.05.2024
Centogene NV

CENTOGENE NV

Centogene N.V - Form 6-K

United states securities and exchange commission washington, d.c. 20549 form 6-k report of foreign private issuer pursuant to rule 13a-16 or 15d-16 under the securities exchange ac ...

02.05.2024
Condividi